摘要
目的:分析头孢哌酮钠舒巴坦钠致血小板降低不良反应(adverse drug reaction,ADR)的发生情况及临床特点,为临床安全用药提供参考。方法:以头孢哌酮舒巴坦、血小板降低为关键词,检索Embase、PubMed、知网、万方、维普数据库,收集国内外相关个案报道进行分析总结。结果:共筛选出有效文献51篇,61例患者,共66例次。61例患者中男性多于女性(男性38例,女性23例),年龄≥65岁(68.85%)居多。所有ADR事件中主要累及系统及临床表现共计80例次,其中一般表现44例次(55.00%),严重36例次(45.00%)。ADR发生在给药后10 min至14 d不等,停药或对症处理后痊愈或好转64例次(96.97%),死亡2例次(3.03%)。61例患者给予头孢哌酮钠舒巴坦钠后其中有45例发生ADR,经处理后血小板计数升高或至正常值。结论:头孢哌酮钠舒巴坦钠致血小板降低ADR临床表现多样且易被忽略,临床药师应加强用药监护,及时发现ADR并采取适当防治措施,确保用药安全。
Objective:To analyze the incidence and clinical characteristics of adverse death reaction(ADR)induced by Sulbactam and Cefoperazone to provide reference for clinical safe medication.Methods:Embase,PubMed,CNKI,Wanfang and Weipu databases were searched using the key words of Sulbactam and Cefoperazone,thrombocytopenia.The relevant case reports in domestic and foreign countries were collected for analysis and summary.Results:A total of 51 valid literatures including 61 patients with 66 ADR were selected.Among the 61 patients,the males were more than females(38 males and 23 females).Of all the ADR events,80 had main affection of the organ system and clinical manifestations,of which 44 had general manifestations(55.00%)and 36 severe ones(45.00%).The 66 cases of ADR occurred in 10 minutes to 14 days after administration.64 patients(96.97%)were cured or improved after drug withdrawal or symptomatic treatment,and 2(3.03%)died.ADR occurred in 45 of 61 patients after administration of Sulbactam and Cefoperazone,and their platelet count increased or returned to normal value after treatment.Conclusion:The clinical manifestations of thrombocytopenia caused by Sulbactam and Cefoperazone are various and easy to be ignored.Clinical pharmacists should strengthen the monitoring of drug use and detect ADR in time.Meanwhile,they should take appropriate prevention and treatment measures to ensure drug safety.
作者
唐彩丽
王红卫
景锲
龚亚君
杨宏忠
乔逸
王婧雯
TANG Cai-li;WANG Hong-wei;JING Qie;GONG Ya-jun;YANG Hong-zhong;QIAO Yi;WANG Jing-wen(Department of Pharmacy,General Global Xi’an Beihuan Hospital,Xi’an 710032,China;Department of Pharmacy,Xijing Hospital,Air Force Medical University,Xi’an 710032,China;Orthopedics Trauma Department,General Global Xi’an Beihuan Hospital,Xi’an710032,China;Department of Pharmacy,The First People’s Hospital of Jingzhou,Jingzhou 434000,China;Department of Pharmacy,Tongchuan Mining Bureau Central Hospital,Tongchuan 727000,China)
出处
《中国药物应用与监测》
CAS
2023年第4期278-282,共5页
Chinese Journal of Drug Application and Monitoring
基金
国家自然科学基金(72074218)。
关键词
头孢哌酮舒巴坦
血小板降低
药物不良反应
文献分析
Sulbactam and cefoperazone
Thrombocytopenia
Adverse drug reaction
Literature analysis
作者简介
唐彩丽,女,主管药师,研究方向:临床药学。E-mail:1143158801@qq.com;通信作者:乔逸,男,副主任药师,研究方向:临床药学与药事管理研究。E-mail:694305040@qq.com。
